Q3 EPS Estimates for Pyxis Oncology Raised by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Research analysts at HC Wainwright boosted their Q3 2026 EPS estimates for Pyxis Oncology in a research report issued on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.26) per share for the quarter, up from their previous estimate of ($0.27). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.08) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.73) EPS, FY2028 earnings at ($0.35) EPS and FY2029 earnings at $0.23 EPS.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05).

A number of other analysts have also weighed in on PYXS. Weiss Ratings lowered shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wells Fargo & Company assumed coverage on Pyxis Oncology in a research report on Monday, August 3rd. They issued an “overweight” rating and a $12.00 price objective on the stock. Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Wedbush initiated coverage on Pyxis Oncology in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 price objective for the company. Finally, Leerink Partners cut their target price on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, July 2nd. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.50.

Pyxis Oncology Stock Up 12.7%

Pyxis Oncology stock opened at $3.37 on Thursday. The stock has a 50-day simple moving average of $2.64 and a 200 day simple moving average of $2.01. The stock has a market capitalization of $213.49 million, a price-to-earnings ratio of -2.39 and a beta of 1.31. Pyxis Oncology has a 12-month low of $1.03 and a 12-month high of $5.55.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PYXS. Renaissance Technologies LLC boosted its position in Pyxis Oncology by 22.0% during the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock worth $1,297,000 after acquiring an additional 160,300 shares during the last quarter. J. Derek Lewis & Associates Inc. bought a new position in Pyxis Oncology in the fourth quarter valued at $61,000. XTX Topco Ltd increased its stake in Pyxis Oncology by 1,533.0% in the 4th quarter. XTX Topco Ltd now owns 289,033 shares of the company’s stock valued at $332,000 after buying an additional 271,334 shares during the last quarter. Toronto Dominion Bank bought a new stake in Pyxis Oncology during the 4th quarter worth about $86,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Pyxis Oncology during the 4th quarter worth about $116,000. 39.07% of the stock is currently owned by institutional investors.

Pyxis Oncology News Summary

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $1.08 from a loss of $1.10 and its FY2027 forecast to a loss of $0.73 from a loss of $0.88. The firm also improved estimates for several 2027 quarters, signaling expectations for reduced operating losses. MarketBeat Pyxis Oncology analyst estimates
• Positive Sentiment: Longer-term projections were upgraded, including FY2028 EPS to a loss of $0.35 from a loss of $0.44 and FY2029 EPS to positive earnings of $0.23 from $0.20. These changes reinforce the analyst’s view that Pyxis could reach profitability in the forecast period. HC Wainwright reaffirms Buy rating for Pyxis Oncology
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $7.00 price objective. The continued bullish stance may support investor sentiment toward the biotechnology company. Benzinga analyst rating report
• Neutral Sentiment: Despite the improved forecasts, Pyxis Oncology remains unprofitable, with consensus estimates calling for a $1.22 per-share loss for the current fiscal year. The company’s latest reported quarter also missed expectations, highlighting ongoing execution and financing risks.
• Negative Sentiment: HC Wainwright made a minor reduction to its FY2030 EPS estimate, lowering projected earnings to $0.76 from $0.77. The change is small but contrasts with the broader upgrades.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.